| Primary |
| Thrombosis Prophylaxis |
19.0% |
| Prophylaxis |
16.2% |
| Myocardial Ischaemia |
11.2% |
| Hypertension |
10.6% |
| Atrial Fibrillation |
8.9% |
| Platelet Aggregation Inhibition |
6.1% |
| Hypertensive Heart Disease |
4.5% |
| Acute Myocardial Infarction |
3.9% |
| Stent Placement |
2.8% |
| Ischemic Heart Disease |
2.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.2% |
| Angioplasty |
1.7% |
| Benign Prostatic Hyperplasia |
1.7% |
| Product Used For Unknown Indication |
1.7% |
| Type 1 Diabetes Mellitus |
1.7% |
| Anxiety |
1.1% |
| Arthralgia |
1.1% |
| Cardiac Disorder |
1.1% |
| Cerebral Ischaemia |
1.1% |
| Chronic Obstructive Pulmonary Disease |
1.1% |
|
| Subdural Haematoma |
12.7% |
| Rectal Haemorrhage |
9.9% |
| Vomiting |
9.9% |
| Presyncope |
8.5% |
| Melaena |
7.0% |
| Anaemia |
5.6% |
| Epistaxis |
4.2% |
| International Normalised Ratio Increased |
4.2% |
| Loss Of Consciousness |
4.2% |
| Sopor |
4.2% |
| Thrombocytopenia |
4.2% |
| Cerebral Haemorrhage |
2.8% |
| Gastritis |
2.8% |
| Hemiplegia |
2.8% |
| Intraventricular Haemorrhage |
2.8% |
| Malaise |
2.8% |
| Pallor |
2.8% |
| Shock Haemorrhagic |
2.8% |
| Subarachnoid Haemorrhage |
2.8% |
| Urticaria |
2.8% |
|
| Secondary |
| Product Used For Unknown Indication |
28.3% |
| Thrombosis Prophylaxis |
16.2% |
| Prophylaxis |
7.2% |
| Hypertension |
6.6% |
| Angioplasty |
5.2% |
| Atrial Fibrillation |
4.5% |
| Acute Myocardial Infarction |
3.1% |
| Pneumonia |
3.1% |
| Pneumonitis |
3.1% |
| Diabetes Mellitus |
2.8% |
| Drug Use For Unknown Indication |
2.8% |
| Type 2 Diabetes Mellitus |
2.8% |
| Intentional Self-injury |
2.4% |
| Myocardial Infarction |
2.4% |
| Arthralgia |
1.7% |
| Cardiac Disorder |
1.7% |
| Influenza |
1.7% |
| Osteoarthritis |
1.7% |
| Anticoagulant Therapy |
1.4% |
| Essential Hypertension |
1.4% |
|
| Vertigo |
10.6% |
| Sopor |
9.1% |
| Rectal Haemorrhage |
7.6% |
| Tendonitis |
7.6% |
| Melaena |
6.1% |
| Presyncope |
6.1% |
| Stevens-johnson Syndrome |
6.1% |
| Tachycardia |
6.1% |
| Vomiting |
6.1% |
| Epistaxis |
4.5% |
| Abdominal Pain Upper |
3.0% |
| Anaemia |
3.0% |
| Haematemesis |
3.0% |
| Hemiparesis |
3.0% |
| Hypertensive Crisis |
3.0% |
| Hypotension |
3.0% |
| International Normalised Ratio Increased |
3.0% |
| Iron Deficiency Anaemia |
3.0% |
| Pruritus Generalised |
3.0% |
| Renal Haematoma |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
51.2% |
| Hypertension |
15.9% |
| Diabetes Mellitus |
5.0% |
| Depression |
2.7% |
| Prophylaxis |
2.3% |
| Type 2 Diabetes Mellitus |
2.2% |
| Atrial Fibrillation |
2.1% |
| Plasma Cell Myeloma |
2.0% |
| Drug Use For Unknown Indication |
1.6% |
| Myocardial Ischaemia |
1.6% |
| Acute Myocardial Infarction |
1.5% |
| Dyslipidaemia |
1.5% |
| Hypercholesterolaemia |
1.5% |
| Rheumatoid Arthritis |
1.5% |
| Epilepsy |
1.4% |
| Multiple Myeloma |
1.4% |
| Pain |
1.2% |
| Thrombosis Prophylaxis |
1.2% |
| Benign Prostatic Hyperplasia |
1.1% |
| Cardiac Failure |
1.1% |
|
| Syncope |
16.7% |
| Vomiting |
9.4% |
| Presyncope |
8.9% |
| Sopor |
8.9% |
| Renal Failure Acute |
6.9% |
| Rhabdomyolysis |
5.4% |
| Thrombocytopenia |
5.4% |
| Hypoglycaemia |
4.4% |
| Tremor |
3.9% |
| Vertigo |
3.9% |
| Acute Myocardial Infarction |
3.0% |
| Renal Failure |
3.0% |
| Sinus Bradycardia |
3.0% |
| Hyponatraemia |
2.5% |
| Loss Of Consciousness |
2.5% |
| Malaise |
2.5% |
| Pain |
2.5% |
| Shock |
2.5% |
| Somnolence |
2.5% |
| Toxicity To Various Agents |
2.5% |
|
| Interacting |
| Prophylaxis |
28.1% |
| Product Used For Unknown Indication |
15.6% |
| Thrombosis Prophylaxis |
12.5% |
| Atrial Fibrillation |
9.4% |
| Depression |
6.3% |
| Hypercholesterolaemia |
6.3% |
| Myocardial Ischaemia |
6.3% |
| Platelet Aggregation Inhibition |
6.3% |
| Chronic Obstructive Pulmonary Disease |
3.1% |
| Ischaemic Cardiomyopathy |
3.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.1% |
|
| International Normalised Ratio Increased |
25.0% |
| Subarachnoid Haemorrhage |
25.0% |
| Epistaxis |
12.5% |
| Haematuria |
12.5% |
| Haemoglobin Decreased |
12.5% |
| Thrombosis |
12.5% |
|
